Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Palvella Therapeutics (PVLA) Other financing activities (2026)

Palvella Therapeutics has reported Other financing activities over the past 2 years, most recently at $3000.0 for Q3 2014.

Quarterly Other financing activities changed N/A to $3000.0 in Q3 2014 from the year-ago period, while the trailing twelve-month figure was $5474.0 through Sep 2014, changed N/A year-over-year, with the annual reading at $154000.0 for FY2025, N/A changed from the prior year.
Other financing activities was $3000.0 for Q3 2014 at Palvella Therapeutics, up from $400.0 in the prior quarter.
Over five years, Other financing activities peaked at $3000.0 in Q3 2014 and troughed at $400.0 in Q1 2014.